创新药企云顶新耀-B（01952.HK）今日盘中大跌5.07%，延续了昨日发布2024年度业绩报告后的下跌趋势。尽管公司营收实现大幅增长，但亏损持续扩大引发了投资者的担忧。
根据云顶新耀发布的2024年度业绩报告，公司实现营业收入7.07亿元人民币，同比增长461.16%。然而，公司权益持有人应占年内亏损约10.41亿元，较上年同期的8.44亿元亏损进一步扩大。每股基本亏损为3.24元。值得注意的是，公司的分销及销售开支大幅增长119.9%至5.08亿元，主要由于扩大商业化团队和活动所致。
云顶新耀表示，收入增长主要受益于依嘉®销售强劲增长及耐赋康®在中国大陆成功上市。但亏损扩大主要是由于2024年上半年与mRNA COVID-19疫苗相关的无形资产出现一次性、非经常性减值亏损。尽管公司在商业化方面取得进展，但持续的亏损状况使投资者对其长期盈利能力产生疑虑，导致股价承压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.